Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II Study of Allogeneic Stem Cell Transplantation for Patients With Hematologic Diseases and Renal Cell Carcinoma, Using Haploidentical Family Donors and Sub-Myeloablative Conditioning With Campath 1H.

X
Trial Profile

Phase I/II Study of Allogeneic Stem Cell Transplantation for Patients With Hematologic Diseases and Renal Cell Carcinoma, Using Haploidentical Family Donors and Sub-Myeloablative Conditioning With Campath 1H.

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alemtuzumab (Primary) ; Fludarabine; Granulocyte macrophage colony stimulating factor
  • Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Fanconi's anaemia; Graft-versus-host disease; Haematological malignancies; Hairy cell leukaemia; Hodgkin's disease; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Plasma cell leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma; Renal cell carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms HIMSUM
  • Most Recent Events

    • 08 Mar 2013 Planned number of patients changed from 20 to 45 as reported by ClinicalTrials.gov.
    • 12 Apr 2012 Planned end date changed from 1 Dec 2012 to 1 Dec 2015 as reported by ClinicalTrials.gov.
    • 22 Dec 2010 Planned End Date changed to 1 Dec 2012 as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top